arrow_back Back to App

Kidney Care Improvement: Research, Treatment, and Insurance Access

This act aims to enhance care for individuals with kidney disease. It introduces new screening tests, facilitates access to disease education, and supports innovative therapies. Additionally, it expands access to Medicare supplemental insurance for kidney disease patients, potentially reducing their treatment costs.
Key points
Kidney disease screenings included in annual Medicare wellness visits.
Easier access to kidney disease education, including at dialysis facilities.
Support for new, innovative drugs and technologies in kidney disease treatment.
Study to increase kidney transplantation rates.
Incentives for nephrology professionals to work in underserved areas.
Guaranteed access to Medicare supplemental policies (Medigap) for individuals with end-stage renal disease, regardless of age.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_5027
Sponsor: Rep. Miller, Carol D. [R-WV-1]
Process start date: 2023-07-27
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Chronic Kidney Disease Improvement in Research and Treatment Act of 2023

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_5027.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-07-27.

What are the main provisions?

Key points include:

  • Kidney disease screenings included in annual Medicare wellness visits.
  • Easier access to kidney disease education, including at dialysis facilities.
  • Support for new, innovative drugs and technologies in kidney disease treatment.
  • Study to increase kidney transplantation rates.
  • Incentives for nephrology professionals to work in underserved areas.
  • Guaranteed access to Medicare supplemental policies (Medigap) for individuals with end-stage renal disease, regardless of age.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Miller, Carol D. [R-WV-1].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

CATEGORIES

Health Benefits